Physician profile
William D Mosier
NPI 1063553378
$3,757.19
in general payments reported to CMS, 2019-2025
20 companies · $873 in 2025
The $873 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $94.97 · 2021: $480 · 2022: $446 · 2023: $546 · 2024: $917 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,335.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,412.82 | 2019-2025 | Cequa, Bromsite |
| Abbvie INC. | $706.19 | 2022-2025 | |
| Allergan, INC. | $323.80 | 2020-2022 | |
| Dompe US, INC. | $190.41 | 2021-2025 | Oxervate |
| Alcon Vision LLC | $179.09 | 2021-2025 | Rocklatan, Hydrus Microstent, Eysuvis |
| Oyster Point Pharma, INC. | $116.07 | 2023-2024 | Tyrvaya |
| Horizon Therapeutics Plc | $102.80 | 2021-2023 | Tepezza |
| Thea Pharma INC. | $101.69 | 2022-2025 | Iyuzeh |
| Bausch & Lomb Americas INC. | $92.48 | 2024-2025 | Miebo, Vyzulta |
| Amgen INC. | $91.98 | 2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $87.61 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $77.84 | 2025 | Xdemvy |
| Abb Con-Cise Optical Group LLC | $63.15 | 2025 | Contact Lens |
| Optos, INC. | $46.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.86 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $40.38 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Aerie Pharmaceuticals, INC. | $30.90 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $19.22 | 2024 | Purified Cortrophin Gel |
| Glaukos Corporation | $17.50 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $12.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mosier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.